All In Biotech

Investigational drug · Phase 3

Combined metabolic activators

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer Disease, Gout Disease.

Phase 3

Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

2 still active

All registered trials

2

Any phase or sponsor naming "Combined metabolic activators"

First trial start

2025

Sep 12, 2025

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Combined metabolic activators", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Alzheimer Disease
  • Gout Disease

Approved drugs for the same conditions: Alzheimer's disease · Gout · Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "Combined metabolic activators" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 11 on PubMed

Also in development for Alzheimer Disease

  • KarX-ECBMS-986519, Xanomeline Enteric-coatedPhase 39 trials

    Bristol Myers Squibb · Alzheimer Disease, Alzheimer's Disease, Irritability Associated With Autism Spectrum Disorder

  • ITI-1284JNJ-99245354Phase 36 trials

    Intra-Cellular Therapies, Inc. · Generalized Anxiety Disorder, Agitation Associated With Alzheimer's Dementia, Psychotic Disorders

  • AXS-05dextromethorphan-bupropionPhase 33 trials

    Axsome Therapeutics, Inc. · Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Smoking Cessation

  • MasitinibAB1010Phase 33 trials

    AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease

  • SPG302TazbentetolPhase 33 trials

    Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis

  • DMB-IINN: Latrepirdine, DimebonPhase 32 trials

    Bigespas LTD · Alzheimer Type Dementia, Alzheimer Disease, Dementia of Alzheimer Type

  • AR1001Phase 31 trial

    AriBio Co., Ltd. · Alzheimer Disease

  • XTR006[18F]MK 6240, FlorquinitauPhase 31 trial

    Sinotau Pharmaceutical Group · Alzheimer Disease, Neurofibrillary Tangle

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.